AU
MDGL icon

AlphaGrep UK’s Madrigal Pharmaceuticals MDGL Stock Holding History

AlphaGrep UK’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-758
Closed -$397K – 867
2026
Q1 		$397K Buy
+758
New +$362K 0.11% 362

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

AlphaGrep UK's MDGL Position: Q2 2026 in Review

AlphaGrep UK sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 758 shares — an estimated $397K sold.

AlphaGrep UK first reported a position in MDGL in Q1 2026 and held it in 1 quarter. The position peaked at $397K in Q1 2026. 374 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • AlphaGrep UK reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • AlphaGrep UK sold 758 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $397K.
  • AlphaGrep UK first reported a position in Madrigal Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • AlphaGrep UK's Madrigal Pharmaceuticals position peaked at $397K in Q1 2026.
  • 374 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.